Does Medicaid Cover Rehab?

Medicaid operates as the single largest payer for addiction treatment in the U.S., with 85+ million covered across all 50 states + DC, but benefit design and expansion status vary substantially. Its parity compliance framework is enforced under MHPAEA; specific medical-necessity criteria must — under the 2024 Final Rule — be disclosed to plan participants upon request. The paragraphs that follow disaggregate the practical coverage framework.

Parity enforcement — what the 2024 rule changed

Medicaid's parity compliance framework is governed federally through Department of Labor enforcement (for ERISA plans) and through state insurance commissioner oversight (for individual and small-group markets). Medicaid's compliance posture is mid-range — neither the most restrictive of the majors nor the most permissive — and the experience varies meaningfully by specific plan product. The 2024 rule's operational consequences for Medicaid include: (a) mandatory disclosure of medical-necessity criteria; (b) documented comparability analysis for NQTLs; (c) accelerated external-review pathways for denied behavioral-health claims.

Medicaid plan types

The Medicaid product portfolio — Traditional fee-for-service, Medicaid Managed Care (MCO), 1115 SUD Waivers, CHIP, Dual-Eligible (Medicaid + Medicare) — reflects differentiated benefit design by market segment (employer group, individual, Medicare, Medicaid-managed, military administration). Network adequacy assessments and medical-necessity criteria can vary meaningfully across these products. The Summary of Benefits and Coverage (SBC) document for the specific product should be the baseline reference for benefit verification.

A note on medication-assisted treatment

Medication-assisted treatment (MAT) coverage is a specific focus of the 2024 parity rule, which flagged restrictive MAT formulary tiering as a common parity violation. Medicaid's MAT coverage: all state Medicaid programs now cover buprenorphine, methadone, and naltrexone for opioid use disorder. Plan participants should verify formulary tier, prior-authorization requirements, and step-therapy protocols for specific MAT medications (buprenorphine-naloxone, methadone via OTP, extended-release naltrexone, extended-release buprenorphine) prior to treatment initiation.

When Medicaid denies — appeal playbook

Under ERISA (for employer-sponsored Medicaid plans) and state insurance law (for individual/small-group Medicaid products), the appeal structure is: (1) internal review, 60-day window; (2) expedited internal review, 72-hour turnaround for urgent medical situations; (3) second-level review; (4) external review by IRO or state commissioner; (5) for ERISA plans, federal court under 29 U.S.C. § 1132(a)(1)(B). The 2024 MHPAEA Final Rule added a parity-specific enforcement pathway administered by the Department of Labor.

Before admission

The operational prerequisites for a Medicaid admission are: (a) confirmed in-network status for the specific product (HMO/PPO/etc.); (b) documented prior authorization with specific day-count authorized; (c) written Verification of Benefits from the facility; (d) current formulary review for any MAT medication. Proceeding on verbal confirmation alone is a common source of cost-sharing disputes at claim adjudication.